Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging
The implementation of theranostics in oncologic nuclear medicine has exhibited immense potential in improving patient outcomes in prostate cancer with the implementation of [<sup>68</sup>Ga]Ga-PSMA-11 PET and [<sup>177</sup>Lu]Lu-PSMA-617 into clinical practice. However, the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Methods and Protocols |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2409-9279/8/3/58 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431786049765376 |
|---|---|
| author | Jason P. Meier Mohammed Bhuiyan Richard Freifelder Hannah J. Zhang Lucas Gonzalez Antonino Pusateri Hsiu-Ming Tsai Lara Leoni Kaustab Ghosh Erica Markiewicz Christopher Henning Yuhan Zhang Ralph Weichselbaum Jerry Nolen David A. Rotsch Chien-Min Kao Russell Z. Szmulewitz Chin-Tu Chen Satish K. Chitneni |
| author_facet | Jason P. Meier Mohammed Bhuiyan Richard Freifelder Hannah J. Zhang Lucas Gonzalez Antonino Pusateri Hsiu-Ming Tsai Lara Leoni Kaustab Ghosh Erica Markiewicz Christopher Henning Yuhan Zhang Ralph Weichselbaum Jerry Nolen David A. Rotsch Chien-Min Kao Russell Z. Szmulewitz Chin-Tu Chen Satish K. Chitneni |
| author_sort | Jason P. Meier |
| collection | DOAJ |
| description | The implementation of theranostics in oncologic nuclear medicine has exhibited immense potential in improving patient outcomes in prostate cancer with the implementation of [<sup>68</sup>Ga]Ga-PSMA-11 PET and [<sup>177</sup>Lu]Lu-PSMA-617 into clinical practice. However, the correlation between radiopharmaceutical biodistributions seen with [<sup>68</sup>Ga]Ga-PSMA-11 PET imaging and downstream [<sup>177</sup>Lu]Lu-PSMA-617 therapy remains imperfect. This suggests that prostate cancer theranostics could potentially be further refined through the implementation of true theranostics, tandem pairs of diagnostic and therapeutic radiopharmaceuticals that utilize the same ligand and element, thus yielding identical pharmacokinetics. The radioscandiums are one such group of true theranostic radiopharmaceuticals. The radioscandiums consist of two β+ emitting scandium isotopes (<sup>43</sup>Sc/<sup>44</sup>Sc), as well as a β<sup>−</sup> emitting therapeutic isotope (<sup>47</sup>Sc), which can all conjugate with PSMA-targeting PSMA-617. This potential has led to extensive investigations into the production of the radioscandiums as well as pre-clinical assessments with several ligands; however, there is a lack of literature extensively describing the complete synthesis of scandium radiopharmaceuticals. which therefore limits the accessibility of radioscandium research in theranostics. As such, this work aims to present an easily translatable protocol for the synthesis of [<sup>43</sup>Sc]Sc-PSMA-617 from a [<sup>42</sup>Ca]CaCO<sub>3</sub> starting material, including target formation, nuclear production via <sup>42</sup>Ca(d,n)<sup>43</sup>Sc reaction, chemical separation, radiolabeling, solvent reformulation, and target recycling. |
| format | Article |
| id | doaj-art-a842e8620acd49fc9aad33e4237ad540 |
| institution | Kabale University |
| issn | 2409-9279 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Methods and Protocols |
| spelling | doaj-art-a842e8620acd49fc9aad33e4237ad5402025-08-20T03:27:32ZengMDPI AGMethods and Protocols2409-92792025-06-01835810.3390/mps8030058Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET ImagingJason P. Meier0Mohammed Bhuiyan1Richard Freifelder2Hannah J. Zhang3Lucas Gonzalez4Antonino Pusateri5Hsiu-Ming Tsai6Lara Leoni7Kaustab Ghosh8Erica Markiewicz9Christopher Henning10Yuhan Zhang11Ralph Weichselbaum12Jerry Nolen13David A. Rotsch14Chien-Min Kao15Russell Z. Szmulewitz16Chin-Tu Chen17Satish K. Chitneni18Department of Radiology, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USAIntegrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USAIntegrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USAIntegrated Small Animal Imaging Research Resource, Office of Shared Research Facilities, The University of Chicago, Chicago, IL 60637, USADepartment of Medicine, The University of Chicago, Chicago, IL 60637, USADepartment of Medicine, The University of Chicago, Chicago, IL 60637, USAUChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USAUChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USAUChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USAUChicago/Argonne Joint Radioisotope Initiative (JRI), Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USADepartment of Radiology, The University of Chicago, Chicago, IL 60637, USAThe implementation of theranostics in oncologic nuclear medicine has exhibited immense potential in improving patient outcomes in prostate cancer with the implementation of [<sup>68</sup>Ga]Ga-PSMA-11 PET and [<sup>177</sup>Lu]Lu-PSMA-617 into clinical practice. However, the correlation between radiopharmaceutical biodistributions seen with [<sup>68</sup>Ga]Ga-PSMA-11 PET imaging and downstream [<sup>177</sup>Lu]Lu-PSMA-617 therapy remains imperfect. This suggests that prostate cancer theranostics could potentially be further refined through the implementation of true theranostics, tandem pairs of diagnostic and therapeutic radiopharmaceuticals that utilize the same ligand and element, thus yielding identical pharmacokinetics. The radioscandiums are one such group of true theranostic radiopharmaceuticals. The radioscandiums consist of two β+ emitting scandium isotopes (<sup>43</sup>Sc/<sup>44</sup>Sc), as well as a β<sup>−</sup> emitting therapeutic isotope (<sup>47</sup>Sc), which can all conjugate with PSMA-targeting PSMA-617. This potential has led to extensive investigations into the production of the radioscandiums as well as pre-clinical assessments with several ligands; however, there is a lack of literature extensively describing the complete synthesis of scandium radiopharmaceuticals. which therefore limits the accessibility of radioscandium research in theranostics. As such, this work aims to present an easily translatable protocol for the synthesis of [<sup>43</sup>Sc]Sc-PSMA-617 from a [<sup>42</sup>Ca]CaCO<sub>3</sub> starting material, including target formation, nuclear production via <sup>42</sup>Ca(d,n)<sup>43</sup>Sc reaction, chemical separation, radiolabeling, solvent reformulation, and target recycling.https://www.mdpi.com/2409-9279/8/3/58theranosticsScandium-43Scandium-44Scandium-47PSMA-617prostate cancer |
| spellingShingle | Jason P. Meier Mohammed Bhuiyan Richard Freifelder Hannah J. Zhang Lucas Gonzalez Antonino Pusateri Hsiu-Ming Tsai Lara Leoni Kaustab Ghosh Erica Markiewicz Christopher Henning Yuhan Zhang Ralph Weichselbaum Jerry Nolen David A. Rotsch Chien-Min Kao Russell Z. Szmulewitz Chin-Tu Chen Satish K. Chitneni Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging Methods and Protocols theranostics Scandium-43 Scandium-44 Scandium-47 PSMA-617 prostate cancer |
| title | Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging |
| title_full | Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging |
| title_fullStr | Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging |
| title_full_unstemmed | Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging |
| title_short | Synthesis of DOTA-Based <sup>43</sup>Sc Radiopharmaceuticals Using Cyclotron-Produced <sup>43</sup>Sc as Exemplified by [<sup>43</sup>Sc]Sc-PSMA-617 for PSMA PET Imaging |
| title_sort | synthesis of dota based sup 43 sup sc radiopharmaceuticals using cyclotron produced sup 43 sup sc as exemplified by sup 43 sup sc sc psma 617 for psma pet imaging |
| topic | theranostics Scandium-43 Scandium-44 Scandium-47 PSMA-617 prostate cancer |
| url | https://www.mdpi.com/2409-9279/8/3/58 |
| work_keys_str_mv | AT jasonpmeier synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT mohammedbhuiyan synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT richardfreifelder synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT hannahjzhang synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT lucasgonzalez synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT antoninopusateri synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT hsiumingtsai synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT laraleoni synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT kaustabghosh synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT ericamarkiewicz synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT christopherhenning synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT yuhanzhang synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT ralphweichselbaum synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT jerrynolen synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT davidarotsch synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT chienminkao synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT russellzszmulewitz synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT chintuchen synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging AT satishkchitneni synthesisofdotabasedsup43supscradiopharmaceuticalsusingcyclotronproducedsup43supscasexemplifiedbysup43supscscpsma617forpsmapetimaging |